CD28 and neoplasm: Recursive tumor cell killing assays showed two intriguing patterns; both 4-1BB costimulatory domain-containing CARs showed superior antigen-dependent T-cell expansion profiles, whereas the CD28 transmembrane domain-containing CAR T cells achieved better control of tumors over the rechallenge timepoints (Fig. 1h).